deltatrials
Terminated PHASE1 INTERVENTIONAL 4-arm NCT05276492

Decreasing Dosing Regimens of Abiraterone 500 mg in Men With Prostate Cancer to Find Lowest Recommended Dose.

Abiraterone Dose De-Escalation Study: A Prospective Study Evaluating Decreasing Dosing Regimens of Abiraterone 500 mg in Men With Prostate Cancer to Find Lowest Recommended Dose.

Sponsor: University of Chicago

Conditions Prostate Adenocarcinoma Prostate Cancer Prostate Cancer Metastatic Prostate Neoplasm
Interventions Abiraterone Oral Tablet Drug Dairy/Log Low-fat meal Prednisone tablet
Updated 9 times since 2022 Last updated: Sep 29, 2025 Started: Jan 24, 2023 Primary completion: Nov 16, 2024 Completion: Nov 16, 2024
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Closed by PI due to not meeting primary endpoint

Other terminated trials from University of Chicago

See all terminations from University of Chicago

Listed as NCT05276492, this PHASE1 trial focuses on Prostate Adenocarcinoma and Prostate Cancer and remains terminated or withdrawn. Sponsored by University of Chicago, it has been updated 9 times since 2023, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Apr 2022 – ~May 2022 · 30 days · monthly snapshotNot Yet Recruiting~May 2022 – ~Apr 2023 · 11 months · monthly snapshotNot Yet Recruiting~Apr 2023 – ~Sep 2023 · 5 months · monthly snapshotNot Yet Recruiting~Sep 2023 – ~Feb 2024 · 5 months · monthly snapshotRecruiting~Feb 2024 – ~Jul 2024 · 5 months · monthly snapshotActive Not Recruiting~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotActive Not Recruiting~Sep 2024 – ~Mar 2025 · 6 months · monthly snapshotActive Not Recruiting~Mar 2025 – ~Nov 2025 · 8 months · monthly snapshotActive Not Recruiting~Nov 2025 – present · 8 months · monthly snapshotTerminated

Change History

9 versions recorded

  1. Nov 2025 — Present [monthly]

    Terminated PHASE1

    Status: Active Not Recruiting → Terminated

  2. Mar 2025 — Nov 2025 [monthly]

    Active Not Recruiting PHASE1

  3. Sep 2024 — Mar 2025 [monthly]

    Active Not Recruiting PHASE1

  4. Jul 2024 — Sep 2024 [monthly]

    Active Not Recruiting PHASE1

  5. Feb 2024 — Jul 2024 [monthly]

    Active Not Recruiting PHASE1

    Status: Recruiting → Active Not Recruiting

▶ Show 4 earlier versions

  1. Sep 2023 — Feb 2024 [monthly]

    Recruiting PHASE1

    Status: Not Yet Recruiting → Recruiting

  2. Apr 2023 — Sep 2023 [monthly]

    Not Yet Recruiting PHASE1

  3. May 2022 — Apr 2023 [monthly]

    Not Yet Recruiting PHASE1

  4. Apr 2022 — May 2022 [monthly]

    Not Yet Recruiting PHASE1

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • University of Chicago
Data source: University of Chicago

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations